Alvotech (ALVO) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2025, filed Mar 31, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ALVO SEC filings page.
Alvotech (ALVO) reported $586.3M in revenue for fiscal year 2025, up 19.7% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Alvotech's 2025 accounting profit arrived before cash generation, while rapid growth still left the balance sheet negatively capitalized.
The 2025 turnaround is more than a profit swing: net income turned positive after a loss in FY2024, yet operating cash flow remained-$50.2M . That earnings-to-cash gap suggests reported earnings included items that had not converted into cash, so profit alone overstates the improvement in operating economics.
Revenue rose from
Financing cash flow supplied
Financial Health Signals
Alvotech does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Alvotech passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
For every $1 of reported earnings, Alvotech used $1.80 of operating cash (-$50.2M OCF vs $27.9M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.
Key Financial Metrics
Earnings & Revenue
None of these metrics is reported for Q4 2025.
Cash & Balance Sheet
Alvotech held $172.4M in cash against $138.0M in long-term debt as of Q4 2025.
Not reported for Q4 2025.
Not reported for Q4 2025.
Margins & Returns
None of these metrics is reported for Q4 2025.
Capital Allocation
None of these metrics is reported for Q4 2025.
ALVO Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Interest Expense, Income Tax, Net Income, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).
ALVO Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2520-F | Q2'256-K | Q4'2420-F | Q2'2410-Q | Q4'2310-K | Q2'2310-Q | Q4'2210-K | Q4'2110-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.5B+21.8% | $1.4B+30.3% | $1.2B+28.6% | $1.1B+17.3% | $950.1M+14.7% | $910.7M | $828.4M+38.5% | $598.0M |
| Current Assets | $574.0M+26.2% | $509.5M+78.6% | $455.0M+133.5% | $285.2M+34.6% | $194.8M-15.6% | $211.9M | $230.7M+92.6% | $119.8M |
| Cash & Equivalents | $172.4M+235.1% | $151.5M+1283.9% | $51.4M+360.9% | $10.9M-81.9% | $11.2M-83.2% | $60.5M | $66.4M+278.4% | $17.6M-44.6% |
| Inventory | $220.1M+72.1% | $155.5M+61.0% | $127.9M+71.8% | $96.6M+21.7% | $74.4M+4.1% | $79.4M | $71.5M+83.0% | $39.1M |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | $16.3M | $33.0M | N/A |
| Goodwill | $12.8M+13.3% | $12.8M+9.4% | $11.3M-6.0% | $11.7M-1.6% | $12.1M+3.6% | $11.9M | $11.6M-5.9% | $12.4M-7.9% |
| Total Liabilities | $1.8B+8.4% | $1.6B-6.5% | $1.6B-13.2% | $1.7B+20.5% | $1.9B+35.2% | $1.4B | $1.4B+89.9% | $733.6M |
| Current Liabilities | $304.1M+57.2% | $279.7M-76.7% | $193.4M-25.9% | $1.2B+442.4% | $260.9M+56.0% | $221.7M | $167.3M+49.6% | $111.8M |
| Non-Current Liabilities | $1.5B+1.9% | $1.3B+172.6% | $1.4B-11.2% | $471.9M-59.6% | $1.6B+32.3% | $1.2B | $1.2B+97.1% | $621.8M |
| Long-Term Debt | $138.0M+23.1% | $136.3M+11.8% | $112.1M+6.2% | $121.9M+39.4% | $105.6M+198.7% | $87.4M | $35.4M-69.2% | $114.8M-79.8% |
| Total Equity | -$284.5M+31.1% | -$173.3M+71.4% | -$412.8M+55.7% | -$605.9M-26.6% | -$932.5M-65.2% | -$478.5M | -$564.4M-316.2% | -$135.6M+84.4% |
| Retained Earnings | -$2.4B+1.1% | -$2.3B+2.7% | -$2.4B-10.5% | -$2.4B-35.5% | -$2.2B-33.4% | -$1.7B | -$1.7B-45.0% | -$1.1B |
Not reported in any period shown, so not listed: Short-Term Investments, Long-Term Investments.
ALVO Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Operating Cash Flow, Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.
ALVO Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, Debt-to-Equity, Asset Turnover, FCF Margin.
Note: Shareholder equity is negative (-$284.5M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Alvotech ALVO | FY2025 | $586.3M | $27.9M | 4.8% | $2.1B | — |
| Supernus Pharmaceuticals, Inc. SUPN | FY2025 | $719.0M | -$38.6M | -5.4% | $2.5B | 53/100 |
| Bausch Health Companies Inc BHC | FY2025 | $10.3B | $157.0M | 1.5% | $2.3B | 51/100 |
| ANI Pharmaceuticals, Inc. ANIP | FY2025 | $883.4M | $78.0M | 8.8% | $1.7B | 69/100 |
| Indivior Pharmaceuticals, Inc. INDV | FY2025 | $1.2B | $210.0M | 17.0% | $4.2B | 44/100 |
| HUTCHMED (China) Limited HCM | FY2025 | $548.5M | $456.9M | 83.3% | $2.5B | 42/100 |
Where Alvotech Ranks
Frequently Asked Questions
What is Alvotech's annual revenue?
Alvotech (ALVO) reported $586.3M in total revenue for fiscal year 2025. This represents a 19.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Alvotech's revenue growing?
Alvotech (ALVO) revenue grew by 19.7% year-over-year, from $489.7M to $586.3M in fiscal year 2025.
Is Alvotech profitable?
Yes, Alvotech (ALVO) reported a net income of $27.9M in fiscal year 2025, with a net profit margin of 4.8%.
How much debt does Alvotech have?
As of fiscal year 2025, Alvotech (ALVO) had $172.4M in cash and equivalents against $138.0M in long-term debt.
What is Alvotech's net profit margin?
Alvotech (ALVO) had a net profit margin of 4.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Alvotech's free cash flow?
Alvotech (ALVO) recorded an outflow of $114.7M in free cash flow during fiscal year 2025. This represents a 60.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Alvotech's operating cash flow?
Alvotech (ALVO) recorded an outflow of $50.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Alvotech's total assets?
Alvotech (ALVO) had $1.5B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Alvotech's capital expenditures?
Alvotech (ALVO) invested $64.5M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Alvotech's current ratio?
Alvotech (ALVO) had a current ratio of 1.89 as of fiscal year 2025, which is generally considered healthy.
What is Alvotech's return on assets (ROA)?
Alvotech (ALVO) had a return on assets of 1.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Alvotech's P/E ratio?
Alvotech (ALVO) trades at 73.9x earnings, its market capitalization divided by net income of $27.9M net income, FY2025. The market capitalization is $2.1B as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Alvotech's price-to-sales ratio?
Alvotech (ALVO) trades at 3.5x sales, its market capitalization divided by revenue of $586.3M revenue, FY2025. The market capitalization is $2.1B as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Why is Alvotech's debt-to-equity ratio negative or not reported?
Alvotech (ALVO) has negative shareholder equity of -$284.5M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Alvotech's Piotroski F-Score?
Alvotech (ALVO) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Alvotech's earnings high quality?
For every $1 of reported earnings, Alvotech (ALVO) used $1.80 of operating cash (-$50.2M OCF vs $27.9M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.